

USHP Annual Meeting
Saturday, August 29, 2015
McKay-Dee Hospital, Education Center
4401 Harrison Boulevard
Ogden, Utah 84403

2015 Registration

Option 1 – Fill out this form and mail with check to:
USHP, PO Box 58356, Salt Lake City, Utah 84158
Registration must be postmarked by August 15, 2015

Option 2 – Register online and pay via credit card or paypal at www.ushp.org

Space is Limited – Register Early!

Name:

Mailing Address:

City, State, Zip:

Preferred Phone:

Dietary Needs:

Email Address:

CPE Monitor ID# (required)

Birth Month/Day (required)

/

Note: CPE Monitor ID, Birth Month/Day required for ACPE credit

After August 15th, add \$25 to the below published price. An e-mail confirmation will be sent to the above indicated address.

Pricing Schedule

	Member	Non-Member
Pharmacists	___ \$100	___ \$250
Technician	___ \$50	___ \$100
Student	___ \$30	___ \$45

Meeting Agenda

USHP Annual Meeting

August 29, 2015

McKay-Dee Hospital, Education Center

4401 Harrison Boulevard

Ogden, Utah 84403

7:00 AM – 8:00 AM	Registration, Check-In, and Breakfast	
8:00 AM – 8:30 AM	Welcome/ Business Meeting (Awards, Install Officers)	
8:30 AM – 9:25 AM	ASHP Guest Lecturer: Pharmacy Technicians: An Essential Ingredient Needed for Pharmacy Practice Advancement (P/T) Douglas Scheckelhoff, RPh, MS, FASHP	
9:35 AM – 10:30 AM	Keynote Presentation: IVIG Medication Safety: Stepwise Guide to Product Selection and Use (P/T) Jerry Siegel, PharmD, FASHP	
10:40 AM – 11:35 AM	Death with Dignity, Pharmacy, and HB 391 (P/T) Jim Ruble, PharmD, JD	
11:35 AM – 1:00 PM	Lunch/Exhibitors/Poster Session Poster Session starts at 12:00	
1:00 PM – 1:55 PM	Medication Safety: The Time is Now (P/T) Sabrina Boehme, PharmD, BCPS	
2:05 PM – 3:00 PM	Aspiration Pneumonia (P/T) Rob Johnston, PharmD	Clinical Trial Evaluation: A Review of Randomization Techniques and Interpretation of Treatment Effect (P) Kiersten Johnston, PharmD
3:10 PM – 4:05 PM	Updates on Lowering the A1C (P/T) Dez Small, PharmD, CDE	Pharmacology of High Altitude Illnesses (P/T) Gary MacDonald, DO, MS

P = Accredited for Pharmacists T = Accredited for Technicians

The target audience is Pharmacists and Pharmacy Technicians.

All educational activities are knowledge-based activities

Educational Objectives

8:30 AM

“Pharmacy Technicians: An Essential Ingredient Needed for Pharmacy Practice Advancement”

Douglas Scheckelhoff, RPh, MS, FASHP

Vice President, Office of Practice Advancement, ASHP

0167-0000-15-006-L04-P/T

Objectives (pharmacists)

1. Define practice model and how the Pharmacy Practice Model Initiative (PPMI) can help advance practice models in hospitals.
2. Identify key drivers of pharmacy practice change over the past 50 years.
3. Explain how the availability of qualified pharmacy technicians will play a pivotal role in enabling the advancement of pharmacist practice.
4. Describe the changes in adoption of automation and technology and how it creates new opportunities for pharmacy.
5. Describe how you can use the information presented to evaluate and advance the practice of pharmacists and technicians in your practice setting.

Objectives (technicians)

1. Define practice model and how the Pharmacy Practice Model Initiative (PPMI) can help advance practice models in hospitals.
 2. Identify trends in pharmacist and pharmacy technician training and certification.
 3. Explain how the availability of qualified pharmacy technicians will play a pivotal role in enabling the advancement of pharmacist practice.
 4. Describe the changes in adoption of automation and technology and how it creates new opportunities for pharmacy.
 5. Describe new, non-traditional roles that pharmacy technicians are being assigned and how they impact pharmacy practice and patient care.
-

9:35 AM

“IVIG Medication Safety: Stepwise Guide to Product Selection and Use”

Jerry Siegel, PharmD, FASHP

Clinical Associated Professor

The Ohio State University Medical Center

Vice President, Safe Medication Management Associates, Inc.

0167-0000-15-005-L01-P/T

Objectives (pharmacists)

1. Differentiate the patient risk factors and how they may influence IVIG product selection.
2. Compare and contrast the main IVIG product features that may affect tolerability.
3. Define and compare the importance and differences of IVIG stabilizers.
4. Describe the impact of rate of IVIG administration as it pertains to adverse events.
5. List FDA-approved indications and the primary off-label uses of IVIG.

Objectives (technicians)

1. Compare the main IVIG product features that may affect tolerability.
 2. Define the differences between IVIG stabilizers.
 3. List 3 FDA-approved indications for IVIG products.
-

10:40 AM

“Death with Dignity, Pharmacy, and HB 391”

Jim Ruble, PharmD, JD

Associate Professor (Clinical), Department of Pharmacotherapy

University of Utah

0167-0000-15-007-L03-P/T

Objectives (pharmacists)

1. Explain the historical development of Death with Dignity (DWD) legislation in the United States.
2. List 3 key stakeholders in the DWD discussion.
3. Describe 2 prevailing ethical philosophies that are at the center of the DWD debate.
4. Identify 3 elements HB 391 and their potential impact to pharmacy practice in Utah.
5. Express an informed professional opinion on DWD when inquired by a patient or professional colleague.

Objectives (technicians)

1. Identify a key stakeholder in the DWD discussion.
 2. Describe a prevailing ethical philosophy involved in DWD debate.
 3. Identify an element in HB 391 and how it may potentially impact pharmacy practice in Utah.
-

1:00 PM

Medication Safety: The Time is Now (P/T)

Sabrina Boehme, PharmD, BCPS

“Medication Safety: The Time is Now”

Sabrina Boehme, PharmD, BCPS

Medication Safety Pharmacist, Primary Children’s Medical Center

0167-0000-15-008-L05-P/T

Objectives (pharmacists and technicians)

1. Define medication safety
2. Identify common look-alike sound-alike medications
3. Describe the potential for harm with computerized provider order entry (cPOE) systems
4. List common methods of categorizing events based on harm
5. Describe the potential for harm in the midst of medication supply shortages
6. Describe vulnerabilities of the pediatric population to medication errors

2:05 PM

“Aspiration Pneumonia” (P/T)

Rob Johnston, PharmD

Pharmacy Clinical Coordinator, Ogden Regional Medical Center

0167-0000-15-009-L01-P/T

Objectives (pharmacists)

1. Describe the mechanism of aspiration pneumonia
2. Classify the different types of aspiration pneumonia
3. Distinguish aspiration pneumonitis from bacterial pneumonia
4. Identify bacteria associated with aspiration pneumonia
5. Devise a treatment plan for aspiration pneumonia
6. Endorse the pharmacist's role in caring for patients with aspiration pneumonia

Objectives (technicians)

1. List the different types of aspiration pneumonia
2. Define characteristics of aspiration pneumonitis
3. Identify bacteria associated with aspiration pneumonia

2:05 PM

“Clinical Trial Evaluation:

A Review of Randomization Techniques and Interpretation of Treatment Effect”

Kiersten Johnston, PharmD

Drug Information Specialist, University of Utah Health Care

0167-0000-15-010-L04-P

Objectives (pharmacists only)

1. Differentiate between strategies aimed at limiting the impact of bias through randomization and statistical adjustment techniques
2. Describe simple randomization, block randomization, and stratified randomization
3. Express, mathematically and verbally, at least 3 different methods of reporting treatment effect
4. Evaluate the strengths and limitations of the different methods of reporting treatment effect

3:10 PM

“Updates on Lowering the A1C”

Dez Small, PharmD, CDE

Clinical Pharmacist, Intermountain Healthcare

Assistant Professor of Pharmacy Practice, Roseman University of Health Sciences

0167-0000-15-011-L01-P/T

Objectives (pharmacists)

1. Describe the mechanism of action of the SGLT-2 inhibitors, DPP IV inhibitors, and GLP-1 inhibitors
2. Compare and contrast the "old" insulin glargine and the "new" insulin glargine
3. Compare and contrast inhaled insulin to the rapid acting injectable insulins
4. Explain where SGLT-2 inhibitors, DPP IV inhibitors, and GLP-1 inhibitors fit into clinical practice

Objectives (technicians)

1. Identify the various GLP-1 agents
 2. Distinguish between the DPP-IV inhibitors and the GLP-1 agonists
 3. Differentiate between the "old" insulin glargine and the "new" insulin glargine
-

3:10 PM

“Pharmacology of High Altitude Illnesses”

Gary MacDonald, DO, MS

Physician, InstaCare

Intermountain Healthcare

0167-0000-15-012-L01-P/T

Objectives (pharmacists)

1. Explain the physiological aspects and compensatory mechanisms of acute hypoxia
2. Compare and contrast acute mountain sickness (AMS), high altitude cerebral edema, and high altitude pulmonary edema (HAPE)
3. Describe the pharmacologic basis for therapy of high altitude illnesses
4. Apply guidelines for appropriate dosing with regards to prophylaxis and treatment of AMS, HACE, and HAPE

Objectives (technicians)

1. Compare and contrast acute mountain sickness, high altitude cerebral edema, and high altitude pulmonary edema
 2. Describe the pharmacologic basis for therapy of high altitude illnesses
 3. List risk factors for acute mountain sickness and high altitude pulmonary edema
-

Conference Details

Registration: Registration fees are discounted before August 15, 2015. To register, complete the registration form and pay by credit card (online only) or send a check to: USHP, PO Box 58356, Salt Lake City, Utah 84158. Space is Limited! Register Early. Registration fee includes admittance to all programming, exhibits, and group meal functions.

Registrations received after the August 15th deadline or on site are subject to a \$25 additional processing fee.

CE Credit: To obtain up to 6 credits of continuing pharmacy education credit (.60 CEUs), the participant must attend the conference, check in at the registration desk, complete and turn in the attendance and evaluation forms, and pass each assessment test with a 75% or higher score. Attendance forms not turned in on site will not be accepted for credit. All credit will be awarded through participants' CPE Monitor accounts. Credits will be uploaded within 60 days after the program.

Cancellation Policy: To receive partial or full refund, registrants must contact USHP in writing prior to August 15, 2015. Requests made after August 9th may not be considered.

Exhibits: The exhibit area offers an opportunity to learn about the latest from the pharmaceutical industry. Representatives from pharmaceutical manufacturers, wholesalers and others may be on hand to demonstrate new products and services.

Special Assistance: It is USHP's policy to comply with the American's with Disabilities Act. If you have any special needs or services while attending, please contact USHP no later than August 15, 2015 at ushp@ushp.org.

Parking: Parking is complimentary and is located adjacent to the building. Directions to the facility will be available on the USHP website (www.ushp.org) prior to the conference.

Accommodations: If you are in need of overnight accommodations, please USHP at ushp@ushp.org.

No grant funding has been sought for this educational program



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.